Table 3.

Published studies on the association between serum bilirubin level and survival of cancer patients

Study	Year	Cancer	Number	Method	TNM stage	Country	Ethnicity	Survival	Factors	Cut‐off value	Significant in univariate analysis	Significant in multivariate analysis
Deng et al.11	2015	NPC	1327	ROC	I‐IV	Guangzhou	Asian	OS	IBI	9.7 μmol/L	Yes	No
Deng et al.11	2015	NPC	1327	ROC	I‐IV	Guangzhou	Asian	DMFS	IBI	9.7 μmol/L	Yes	Yes
Li et al.13	2015	NSCLC	1617	ROC	I‐III	Guangdong	Asian	OS,DFS, LRFS, DMFS	TBIL	9.50 μmol/L	Yes	No
Li et al.13	2015	NSCLC	1617	ROC	I‐III	Guangdong	Asian	OS, DFS, LRFS, DMFS	DBIL	3.45 μmol/L	Yes	No
Li et al.13	2015	NSCLC	1617	ROC	I‐III	Guangdong	Asian	OS, DFS, LRFS, DMFS	IBI	6.95 μmol/L	Yes	Yes
Liu et al.14	2015	Breast cancer	2425	Spline curves	I‐III	Houston	Caucasian	OS	TBIL	0.2 mg/dl	Yes	Yes
Cao et al.12	2016	Rectal cancer	469	ROC	I‐IV	Beijing	Asian	OS	DBIL	2.6 μmol/L	Yes	Yes
Zhang et al.15	2016	CRC	986	X‐tile	II‐III	Shanghai	Asian	OS, DFS	DBIL	3.6 μmol/L	Yes	Yes
This study	2016	CRC	154	X‐tile	IV	Nanjing	Asian	OS	TBIL	12.9 μmol/L	Yes	No
This study	2016	CRC	154	X‐tile	IV	Nanjing	Asian	OS	DBIL	6.1 μmol/L	Yes	Yes
This study	2016	CRC	154	X‐tile	IV	Nanjing	Asian	OS	IBI	4.8 μmol/L	No	No

ROC, receiver operating characteristic; NSCLC, non‐small‐cell lung cancer; NPC, nasopharyngeal carcinoma; CRC, colorectal cancer; TBIL, total bilirubin; DBIL, direct bilirubin; IBI, indirect bilirubin; OS, overall survival; LRFS, locoregional relapse‐free survival; DMFS, distant metastasis‐free survival; DFS, disease‐free survival; RFS, relapse‐free survival.